CNA at 11.5x Earnings: Still Cheap After Q2, or Has the Market Already Caught Up?

Q2 earnings beat, but the quality of the result is still in question

CNA did beat expectations, but the more useful question now is whether the market still has room to reward a quarter that looked solid on the surface but mixed underneath. After Q2 EPS of $1.19 beat the $1.01 estimate by 17.82% and the company reaffirmed its $0.48 quarterly dividend, the stock had already returned 21.94% over 90 days. That makes this less of a surprise setup and more of a test of whether investors will pay up for earnings that were always likely to be acceptable.

What the beat did not fully conceal

The surface-level read was clean, but the operating picture was less so. P&C core income of $426 million versus $448 million and P&C combined ratio of 96.5%, compared with 94.1% point to softer underwriting results. The underlying measure was weaker still, with the P&C underlying combined ratio was 94.2%, compared with 91.7%. That is the kind of deterioration investors usually do not ignore for long.

Bulls can still point to the positives: Catastrophe losses of $60 million pretax versus $62 million in the prior year quarter and P&C segments generated net written premium growth of 4% show the quarter was not broken. Bears will focus on the offsetting weakness: lower underlying underwriting results, a Life & Group core loss of $10 million, and another $77 million after-tax charge related to unfavorable prior period development associated with legacy mass tort. The quarter was good enough to beat estimates, but not strong enough to prove a clear improvement in core operating momentum.

Underwriting discipline helped, but weaker underwriting still needed support from investments

One useful way to read the quarter is to separate what helped the income statement from what the business is still choosing not to write.

Investing buffered the quarter

CNA's results were helped by investments, not carried by underwriting. Net investment income rose 6% to $701 million, while P&C core income of $426 million versus $448 million, reflects lower underlying underwriting results partially offset by higher net investment income. That distinction matters. A stronger investment result can soften a softer core business, but it does not fix pricing or improve renewal strength.

Discipline protected margins, but it did not prove pricing power

Management maintained a conservative underlying loss ratio of 64.1% and kept higher loss picks to account for social inflation and the maturity of casualty claims. That is a disciplined approach, and it is consistent with a company that would rather carry more reserve conservatism now than underprice risk.

But discipline also showed up as lower volume. Management said it is walking away from business where price and terms are inadequate, including a 50% decline in national accounts property new business due to undisciplined market behavior. That can protect margins, but it is not the same thing as clear pricing power. If the company turns away business because the market will not pay more, profit margin can hold up while growth potential stays limited.

Legacy claims still weighed on the quarter

The cleanest headline beat still needs context. Alongside weaker P&C core income, Life & Group core loss of $10 million and Corporate & Other core loss of $92 million show that legacy and corporate items still dragged on results. In plain terms, the core business was still helping fund old claims while trying to build current operating momentum.

CNA valuation looks reasonable, not obviously undervalued

At 11.44x trailing earnings and 11.6x earnings, with trailing EPS of $4.55 and expected earnings growth of 15.46% next year, CNA still looks like a fair-business stock rather than a premium compounder. The dividend helps, including the reaffirmed $0.48 quarterly dividend, but after a 21.94% gain over 90 days, valuation looks more like a balanced scorecard than an obvious bargain.

What appears to be priced in already

The bull case is straightforward: if earnings grow at the currently expected pace, a low-teens P/E does not need a dramatic rerating to support decent returns. In that reading, investors are paying for present earnings power and leaving some room for a modest multiple expansion if the business keeps executing.

The bear case is that the discount may still be justified. Management's decision to shrink exposure where terms are inadequate, including a 50% decline in national accounts property new business, can defend margins but can also constrain volume. That helps explain why the stock can remain around 11.5x earnings: the market may see a solid earnings base, but not yet enough confidence to award a richer multiple.

What could matter before the next report

Before Nov. 2, 2026, investors will likely focus on a short list of proof points:

• whether P&C segments generated net written premium growth of 4% holds up or fades,
• whether the P&C underlying combined ratio was 94.2%, compared with 91.7% stabilizes or keeps worsening,
• whether Net investment income of $701 million continues to cushion softer underwriting, and
• whether legacy mass-tort pressure eases or remains a drag after the $77 million after-tax charge related to unfavorable prior period development associated with legacy mass tort.

What would argue against another rerating

If the next few quarters bring weaker premium growth, less favorable underwriting trends, or continued legacy drag, the stock can easily remain reasonably priced without becoming clearly cheap again. After the recent run, CNA still looks investable, but the easier upside appears to have been partly taken already.